Insider Trading & MNPI — Biotech Scenario

A Clinical Trial Employee Learns the Phase 3 Results Before the Public Announcement. A Family Member Asks If They Should Sell Their Stock. What Do You Do?

A real biotech and pharma compliance scenario — with three decision options and the right answer.

The Situation

You are a clinical operations manager at a publicly traded biotech company overseeing a Phase 3 trial for the company’s lead asset. The trial has missed its primary endpoint. The data is unambiguous. The company will make a public announcement within 72 hours, and the stock price is expected to drop significantly when it does. Your sister calls that evening. She mentions that she recently bought shares in your company because she believes in the pipeline. She asks — casually, not knowing what you know — whether you think the stock is a good hold right now. You have not been asked to share anything. No one is pressuring you. Your sister is not sophisticated about securities law. She’s just asking a question.

Choice ATell her you can’t discuss it right now. Decline to answer without explaining why. This protects the information without confirming or denying that something is happening.

Choice BTell her you’ve heard some things at work, and she should probably talk to her financial advisor. This is indirect, but giving any signal — even a vague one — based on MNPI is a tip-off. The implication is clear even without stating the results.

Choice CSay nothing about what you know, tell her you can’t give financial advice, and contact your compliance officer to disclose that the conversation occurred. Decline to answer and proactively report the contact to compliance.

The Right Call

Choice C — Say nothing and disclose the contact to your compliance officer.

Choice A is close and meaningfully better than Choice B. But the most protective response — for you, for your sister, and for the company — is to decline to engage and report the conversation to compliance. This creates a record that you were contacted, that you did not share information, and that you handled it appropriately. That record matters if the trading activity is ever reviewed. Choice B is a securities violation. Signaling that she “should talk to a financial advisor” in response to a question about your company’s stock — when you possess MNPI — is a tip-off under the law. The SEC and DOJ do not require that you explicitly disclose the trial results.

The question is innocent — and that makes it feel like a non-event.

Your sister isn’t a sophisticated trader. She isn’t asking for inside information. She bought shares because she believed in the company. The question feels like small talk, not a compliance situation. The natural human instinct — especially with family — is to be helpful, or at least not to be cold. But insider trading law does not distinguish between innocent questioners and sophisticated traders. The operative fact is what you know, not what she intended to ask.

“I didn’t trade” is not a complete defense.

Many employees understand that trading on MNPI is illegal. Fewer understand that tipping — sharing the information with someone else who then trades — is equally illegal under the SEC’s tipper-tippee liability framework. The tipper can face civil and criminal liability even if they received nothing in return and didn’t personally trade a single share. Family members are the most common tippees in SEC enforcement actions precisely because the transaction feels personal rather than financial.

The 72-hour window creates real pressure.

The announcement is coming soon. You might rationalize that it’s almost public anyway, or that protecting your sister from a loss is more important than a technicality that will resolve in three days. But the information is MNPI until the moment it is publicly announced. The imminence of the announcement is irrelevant to whether a tip-off occurred.

Decline to answer questions about company performance or prospects when you are in possession of MNPI — even in casual conversations with family or friends.

Do not signal indirectly. Vague warnings, suggesting someone “talk to their advisor,” or any response that implies something is happening, constitute tipping even without disclosing the specific data.

Report the contact to your compliance officer. Document that you were asked, that you declined, and when it happened. Compliance officers would rather receive a report that turns out to be unnecessary than learn about a contact after an SEC inquiry.

Understand your blackout periods. Many companies impose trading blackout windows around material announcements. These windows typically apply to both tipping and trading.

What is material non-public information (MNPI) in the biotech context?

Material non-public information is any information that a reasonable investor would consider important in deciding whether to buy or sell a security — and that has not yet been disclosed to the public. In biotech, this typically includes clinical trial results, regulatory decisions, partnership announcements, and financing events. Phase 3 trial results are among the most significant MNPI a biotech employee can possess because they directly affect the company’s valuation and pipeline.

What is tipper-tippee liability under securities law?

Under the SEC’s insider trading framework, both the tipper (the person who shares MNPI) and the tippee (the person who receives and trades on it) can face liability. The tipper is liable if they shared information in breach of a duty and received a personal benefit — which courts have interpreted broadly to include gifts to family members. Neither party needs to have traded personally to be liable.

Does it matter that I didn’t explicitly share the trial results?

No. The SEC and DOJ look at the substance of the communication, not its form. Signaling that something significant is happening — through vague warnings, changes in behavior, or indirect suggestions to take action — can constitute tipping even without disclosing the specific data. The key question is whether a reasonable person in the tippee’s position would understand that the signal came from someone with material non-public information.

What are the consequences of insider trading or tipping in biotech?

Civil and criminal penalties can include disgorgement of any profits or losses avoided, civil penalties up to three times the profit gained or loss avoided, criminal fines up to $5 million, and imprisonment up to 20 years for individuals. The SEC frequently pursues cases involving clinical trial employees and their family members — it is one of the most common enforcement patterns in biotech compliance.

What should I do if a family member has already traded based on something I said?

Contact your company’s compliance officer and, if appropriate, outside legal counsel immediately. Do not attempt to reverse the trades or instruct the family member to do so — this can constitute obstruction. Early disclosure and cooperation are the most important factors in limiting individual exposure.

How to Use This Scenario in Training

Insider trading policy training establishes the rule. This scenario makes it stick.

This scenario is most valuable for clinical operations, regulatory affairs, finance, and any employee who has access to trial data or other material corporate information before public announcement. The recognition skill is understanding that the MNPI obligation applies to information you share — not just trades you execute — and that family relationships do not create exceptions to MNPI rules.

More Compliance Scenarios

Compliance Training Built for Biotech and Pharma

Xcelus develops scenario-based compliance training for pharmaceutical and biotech organizations — including insider trading, MNPI policy, securities law compliance, and data privacy scenarios built for clinical and operations teams.

View Compliance Programs →
Contact Xcelus